Technology evaluation: MRA, Chugai.

Article Details

Citation

Ding C, Jones G

Technology evaluation: MRA, Chugai.

Curr Opin Mol Ther. 2003 Feb;5(1):64-9.

PubMed ID
12669473 [ View in PubMed
]
Abstract

Chugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.

DrugBank Data that Cites this Article

Drugs